Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin

NCT ID: NCT01855516

Last Updated: 2016-01-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 83 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-09-30
• Study Completion Date: 2015-12-31

Brief Summary

This study is designed to assess: the incidence of abnormal partial thromboplastin time in patients receiving unfractionated heparin (UFH) 5000 U 2 times a day versus 3 times a day 72 hours after administration of the first dose of heparin.

Hypothesis: The basic hypothesis of this study is that patients receiving UFH 5000 U subcutaneously 3 times a day will have a higher proportion of elevated partial thromboplastin time than patients receiving UFH 5000 U subcutaneously twice a day.

Detailed Description

Administration of subcutaneous UFH for antithrombotic prophylaxis is standard therapy in the postoperative setting. Often, a dosage of 5000 U twice a day has been used, with a demonstrated antithrombotic efficacy and an acceptable hemorrhagic complication profile. However, recent surgery guidelines regarding antithrombotic prophylaxis with UFH 5000 U suggest that a thrice daily regimen should be used following major oncologic surgeries. These new guidelines have raised some concerns in anesthesiology, particularly regarding the safety of epidural catheters combined with thrice daily heparin. Optimal analgesia during the early postoperative period following some types of major oncologic surgery involves the placement of epidural catheters. Epidural analgesia provides the best relief of the significant pain which may be present after thoracotomy or supraumbilical laparotomy during the early postoperative period, improving ambulation, coughing, pulmonary function, bowel function as well as short and long-term quality of life. However, the benefits of epidural catheters must outweigh the risk of complications, the most feared being spinal hematoma. Recent guidelines in anesthesiology support the placement of epidural catheters with the concomitant administration of UFH 5000 U two times a day. However, these guidelines do not clearly support the placement of an epidural catheter if a three times a day regimen is used, very little data being available to assess the risk of this practice. Older studies (1973) suggest that a significant proportion of patients (15%) will develop abnormal partial thromboplastin times using a three times a day regimen. However, it is not known if these results are still consistent with more recent laboratory technologies, or how they compare to twice daily heparin. In the absence of even basic data regarding systemic effect on coagulation, it is difficult at this time to begin to determine safe practice regarding the placement of an epidural catheter in presence of a three times a day UFH 5000 U regimen. A recent pilot study conducted in our center showed that 20% (4/20) of patients receiving the thrice daily regimen will develop abnormal partial thromboplastin times at 72 hours following the first dose compared to 5% (1/20) in patients receiving the twice a day regimen. This larger scale study is designed to establish the incidence of abnormalities in partial thromboplastin times 72 hours following the administration of the first dose of heparin for both regimens.

Methods: 130 patients will be enrolled and divided in two equal groups (Group 1: to receive UFH 5000 U subcutaneous two times a day or Group 2: to receive UFH 5000 U subcutaneous three times a day)

As needed for standard anesthesia, surgical and post-operative care, an arterial line will be placed. Immediately prior the first UFH dose, a blood sample for partial thromboplastin time will collected through the arterial line. Since nutritional status may affect the patient's coagulation a blood sample to measure albumin and transthyretin will be collected simultaneously. The first dose of UFH will be given in the operating room by the anesthesiologist.

A second blood sample will be collected by venipuncture at 72 hours following the administration of the first dose of heparin.

Conditions

Thrombosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

UFH 5000 U three times a day

Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.

Group Type: ACTIVE_COMPARATOR

Heparin

Intervention Type: DRUG

UFH 5000 U two times a day

Study subjects will be randomized to receive heparin 5000 U subcutaneous two times a day.

Group Type: ACTIVE_COMPARATOR

Heparin

Intervention Type: DRUG

Interventions

Heparin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients undergoing an elective surgery by thoracoscopy requiring antithrombotic prophylaxis
• Anticipated duration of hospital stay of at least 3 days

Exclusion Criteria

• Pre-existing coagulopathy
• Severe renal failure
• Known allergy to heparin
• History of heparin induced thrombocytopenia

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nathalie Massicotte, MD, FRCPC

Role: PRINCIPAL_INVESTIGATOR

Centre hospitalier de l'Université de Montréal (CHUM)

Locations

Centre Hospitalier de l'Université de Montréal-Hôpital Notre-Dame

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

NM2013-001

Identifier Type: -

Identifier Source: org_study_id